Stockscreener 앱 받기
2.76
9.52%
0.24
시간 외 거래:
2.76
전일 마감가:
$2.52
열려 있는:
$2.55
하루 거래량:
1.98M
Relative Volume:
0.83
시가총액:
$248.18M
수익:
$32.31M
순이익/손실:
$-237.09M
주가수익비율:
-0.9583
EPS:
-2.88
순현금흐름:
$-219.11M
1주 성능:
+7.39%
1개월 성능:
+6.15%
6개월 성능:
+34.63%
1년 성능:
-20.92%
1일 변동 폭
$2.49
$2.76
1주일 범위
$2.39
$2.76
52주 변동 폭
$0.9101
$4.12
Editas Medicine Inc Stock (EDIT) Company Profile
명칭
Editas Medicine Inc
전화
617-401-9000
주소
11 HURLEY ST., CAMBRIDGE, MA
EDIT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.76 | 226.60M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-28 | 개시 | H.C. Wainwright | Buy |
| 2024-12-16 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-13 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-11-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-04 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-05-09 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-10-18 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | 업그레이드 | Stifel | Hold → Buy |
| 2023-06-12 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-13 | 개시 | Citigroup | Neutral |
| 2022-12-06 | 재개 | Credit Suisse | Neutral |
| 2022-11-18 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-09-29 | 개시 | BofA Securities | Neutral |
| 2021-10-19 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-24 | 개시 | Stifel | Hold |
| 2021-09-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-08-09 | 업그레이드 | Truist | Hold → Buy |
| 2021-08-05 | 업그레이드 | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | 개시 | Goldman | Sell |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-26 | 다운그레이드 | Truist | Buy → Hold |
| 2021-01-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | 개시 | Robert W. Baird | Underperform |
| 2020-06-18 | 재개 | SunTrust | Buy |
| 2020-02-21 | 개시 | Wells Fargo | Equal Weight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-10 | 개시 | Guggenheim | Neutral |
| 2018-09-21 | 개시 | Raymond James | Outperform |
| 2018-05-15 | 재확인 | Chardan Capital Markets | Buy |
| 2018-02-13 | 개시 | CLSA | Underperform |
| 2018-01-23 | 업그레이드 | SunTrust | Hold → Buy |
| 2017-07-14 | 개시 | SunTrust | Hold |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-06-02 | 개시 | Jefferies | Hold |
| 2016-02-29 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-29 | 개시 | JP Morgan | Neutral |
| 2016-02-29 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Editas Medicine Inc 주식(EDIT)의 최신 뉴스
Statistical indicators supporting Editas Medicine Inc.’s strengthExit Point & High Win Rate Trade Alerts - Newser
Using portfolio simulators with Editas Medicine Inc. includedJuly 2025 Sector Moves & Growth Focused Entry Reports - Newser
What drives Editas Medicine Inc.’s stock price2025 Top Gainers & Capital Efficient Trading Techniques - خودرو بانک
What are Editas Medicine Inc.’s technical support levelsJuly 2025 Outlook & High Return Stock Watch Alerts - خودرو بانک
Can Editas Medicine Inc. weather a recession2025 Year in Review & Verified Technical Signals - خودرو بانک
Is Editas Medicine Inc. a momentum stockJuly 2025 Recap & Accurate Intraday Trade Tips - خودرو بانک
Can Editas Medicine Inc. expand into new marketsWeekly Stock Report & Weekly Consistent Profit Watchlists - خودرو بانک
Predicting Editas Medicine Inc. trend using moving averages2025 Breakouts & Breakdowns & Low Risk Investment Opportunities - Newser
Volatility Watch: Is Editas Medicine Inc. stock influenced by commodity prices2025 Technical Patterns & Detailed Earnings Play Strategies - خودرو بانک
Wells Fargo & Company Increases Editas Medicine (NASDAQ:EDIT) Price Target to $4.00 - MarketBeat
Is Editas Medicine Inc. forming a bottoming baseQuarterly Profit Summary & Safe Capital Growth Stock Tips - Newser
Editas Medicine: HC Wainwright Raises PT to $5 from $4 on Buy Rating - AInvest
Using Ichimoku Cloud for Editas Medicine Inc. technicalsWeekly Investment Report & Free Low Drawdown Momentum Trade Ideas - Newser
Is Editas Medicine Inc. stock ready for a breakoutJuly 2025 Big Picture & Smart Investment Allocation Tips - Newser
Real time scanner hits for Editas Medicine Inc. explainedMarket Weekly Review & Low Drawdown Trading Techniques - Newser
Editas Medicine at Cantor Global: CRISPR Shift and Financial Resilience By Investing.com - Investing.com Canada
Editas Medicine (NASDAQ:EDIT) Stock Price Crosses Below Fifty Day Moving AverageTime to Sell? - MarketBeat
How to escape a deep drawdown in Editas Medicine Inc.2025 Stock Rankings & Free Verified High Yield Trade Plans - Newser
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $5.10 Consensus Target Price from Analysts - MarketBeat
Editas Medicine at Cantor Global: CRISPR Shift and Financial Resilience - Investing.com
Can volume confirm reversal in Editas Medicine Inc.Quarterly Earnings Report & Free Fast Gain Swing Trade Alerts - Newser
Using data models to predict Editas Medicine Inc. stock movementPortfolio Return Report & Low Risk High Reward Trade Ideas - Newser
Is Editas Medicine Inc. stock entering bullish territoryPortfolio Risk Report & Reliable Price Action Trade Plans - Newser
How to build a custom watchlist for Editas Medicine Inc.Recession Risk & AI Forecast Swing Trade Picks - Newser
Is Editas Medicine Inc. showing signs of accumulation2025 Year in Review & Low Risk High Reward Trade Ideas - Newser
Evaluating Editas Medicine Inc. with trendline analysisQuarterly Profit Summary & Consistent Growth Stock Picks - Newser
Editas Medicine price target raised to $4 from $3 at Wells Fargo - TipRanks
Editas Medicine at Wells Fargo Conference: Gene Editing Milestone - Investing.com
Activity Recap: How does Editas Medicine Inc. score in quality rankingsDay Trade & Free Accurate Trade Setup Notifications - خودرو بانک
what the charts say about editas medicine inc. todayQuarterly Profit Summary & Smart Allocation Stock Reports - Newser
Is now the right time to enter Editas Medicine Inc.Dividend Hike & Low Drawdown Investment Ideas - خودرو بانک
How to track smart money flows in Editas Medicine Inc.Weekly Trade Review & Verified Technical Signals - Newser
Is it time to cut losses on Editas Medicine Inc.2025 Institutional Moves & Risk Controlled Swing Trade Alerts - Newser
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol - Yahoo Finance
Is Editas Medicine Inc. forming a reversal patternTrade Volume Summary & Weekly Stock Breakout Alerts - Newser
What machine learning models say about Editas Medicine Inc.Weekly Stock Report & High Accuracy Swing Trade Signals - Newser
Can Editas Medicine Inc. grow without external fundingJuly 2025 Pullbacks & Real-Time Market Sentiment Reports - خودرو بانک
Editas Medicine’s Strategic Milestone in In Vivo Gene Editing: A Catalyst for Long-Term Value - AInvest
Chart based exit strategy for Editas Medicine Inc.Swing Trade & Reliable Trade Execution Plans - Newser
Macro Review: Is Editas Medicine Inc.’s ROE strong enoughWeekly Profit Report & Growth Oriented Trading Recommendations - خودرو بانک
Applying big data sentiment scoring on Editas Medicine Inc.Earnings Beat & Intraday High Probability Alerts - Newser
Does Editas Medicine Inc. stock have upside surprise potentialTrade Performance Summary & Daily Growth Stock Investment Tips - خودرو بانک
When is the best time to exit Editas Medicine Inc.Quarterly Growth Report & Daily Entry Point Alerts - Newser
Editas Medicine shares rise 1.30% after-hours after unveiling lead development candidate EDIT-401. - AInvest
Editas Medicine shares fall 1.75% intraday after announcing EDIT-401 as lead in vivo development candidate. - AInvest
What the charts say about Editas Medicine Inc. today2025 Earnings Surprises & Technical Pattern Recognition Alerts - Newser
Editas turns to cholesterol therapy, becoming latest gene editing company to pivot to more common diseases - Endpoints News
Editas Medicine : Lead In Vivo Development Candidate Webinar Presentation (8e4429) - MarketScreener
Editas Medicine nominates lead in vivo development candidate - BioWorld MedTech
Editas Medicine’s Strategic Pivot to In Vivo Gene Editing: A Catalyst for Cardiovascular Innovation and Valuation Growth - AInvest
Editas Medicine Inc (EDIT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Editas Medicine Inc 주식 (EDIT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Parison Amy | SVP, Chief Financial Officer |
Sep 03 '25 |
Sale |
2.60 |
458 |
1,189 |
16,369 |
| O'Neill Gilmore Neil | CEO |
Sep 03 '25 |
Sale |
2.60 |
5,592 |
14,517 |
274,690 |
1.40%
자본화:
|
볼륨(24시간):